**t(3;5)(q25;q34)**

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Published in Atlas Database: August 1997

Online version is available at: http://AtlasGeneticsOncology.org/Anomalies/t0305.html

DOI: 10.4267/2042/32030

This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.

© 1997 Atlas of Genetics and Cytogenetics in Oncology and Haematology

---

**Clinics and pathology**

**Disease**

ANLL; may be preceded by MDS; BC-CML

**Phenotype / cell stem origin**

M2, M4, M6 (although a rare subtype) ANLL; trilineage involvement.

**Epidemiology**

Med. age: 35 yrs; balanced sex ratio.

**Prognosis**

CR: 8/12, but median survival is less than 1 yr.

---

**Cytogenetics**

**Cytogenetics, morphological**

Location of breakpoints is difficult to ascertain.

**Additional anomalies**

Most often none; +8.

---

**Genes involved and Proteins**

**MLF1**

**Location:** 3q25

**Protein**

31 kDa; do not contain known functional motifs; widely expressed; cytoplasmic localisation.

**NPM1**

**Location:** 5q34

**Protein**

Nuclear localisation; binds to single and double strand nucleic acids; phosphoprotein that may transport ribonucleoproteins; may also have a role in DNA replication.

---

**Results of the chromosomal anomaly**

**Hybrid gene**

**Description**

5' NPM-3' MLF1 on der(5).

**Fusion protein**

**Expression localisation**

54 kDa with the 175 N-term amino acids from NPM; localization: nucleus, mainly in the nucleolus.

---

**To be noted**

Specific comments: this translocation share some (but not all) common features with t(1;3)(p36;q21), inv(3)(q21q26)..., although the genes involved on chromosome 3 are different.

---

**References**


This article should be referenced as such: